Non-small cell lung cancer stage III – Diagnostics – Overview of Information and Clinical Research

Stage III non-small cell lung cancer represents a complex diagnostic challenge because it sits between localized and advanced disease. Understanding how doctors identify and evaluate this stage is essential for patients and families navigating treatment decisions and preparing for what lies ahead.

Introduction: Who Should Seek Diagnostic Testing

Stage III non-small cell lung cancer is often called locally advanced cancer because it has spread beyond the lungs but remains confined to the chest area. Approximately 20 to 30 percent of people with non-small cell lung cancer (NSCLC)—the most common type of lung cancer—are diagnosed at this stage.^[1]^[2] Understanding when to seek diagnostic testing can make a significant difference in treatment outcomes.

Most people with stage III NSCLC experience noticeable symptoms by the time they receive their diagnosis. If you develop a persistent cough that does not go away, this is the most common warning sign that should prompt you to see a doctor. Other symptoms that warrant medical attention include unexplained weight loss, shortness of breath or wheezing, chest pain, coughing up blood or rust-colored spit, or developing a hoarse voice.^[6] These signs occur because the cancer has grown large enough or spread far enough to affect how your lungs and surrounding structures function.

People at higher risk for lung cancer should be especially vigilant about these symptoms. The biggest risk factor is a history of smoking cigarettes, pipes, or cigars. However, lung cancer can also develop in people who have never smoked, particularly adenocarcinoma, one type of NSCLC. Other risk factors include exposure to secondhand smoke, occupational exposure to substances like asbestos, arsenic, or chromium, radiation exposure from previous medical treatments, and exposure to radon gas in homes or workplaces.^[14] If you fall into any of these risk categories and develop respiratory symptoms, you should not delay seeking medical evaluation.

⚠️ Important

Many people with lung cancer do not experience symptoms in the early stages, which is why the disease is often discovered only after it has advanced. If you have risk factors such as a smoking history or occupational exposures, talk with your doctor about whether you should undergo screening tests even before symptoms appear. Early detection through screening can sometimes catch cancer before it reaches stage III.

Because stage III lung cancer can spread to nearby lymph nodes and structures within the chest, symptoms may vary depending on where the cancer has grown. If the cancer affects nerves near the lungs, you might notice changes in your voice. If it presses on blood vessels or the chest wall, you may experience pain. Understanding that these diverse symptoms can all point to the same underlying problem helps explain why thorough diagnostic testing is necessary once lung cancer is suspected.

Classic Diagnostic Methods for Stage III NSCLC

When your doctor suspects you may have lung cancer based on your symptoms and medical history, they will begin with a physical examination and then order a series of tests to confirm the diagnosis and determine the stage. The diagnostic process involves multiple steps, each designed to answer specific questions about the cancer’s location, size, and spread.

Initial Imaging Tests

The first test most people receive is a chest X-ray. This simple imaging procedure can reveal abnormal masses or shadows in the lungs that suggest cancer might be present. However, a chest X-ray alone cannot definitively diagnose cancer or determine its stage. If the X-ray shows something concerning, your doctor will order more detailed imaging studies.^[21]

A computed tomography (CT) scan is typically the next step. This test creates detailed cross-sectional images of your chest, allowing doctors to see the size and location of tumors much more clearly than with a standard X-ray. For stage III NSCLC, doctors often order a “contrast-enhanced” CT scan, which involves injecting a special dye into your vein before the scan. This dye helps highlight blood vessels, lymph nodes, and other structures, making it easier to see whether cancer has spread to nearby tissues.^[21]

Beyond CT scans, other imaging tests play important roles in evaluating stage III lung cancer. A positron emission tomography (PET) scan uses a small amount of radioactive material to identify areas where cancer cells are actively growing. This test is particularly useful for detecting cancer in lymph nodes and determining whether the disease has spread beyond the chest. Some medical centers combine PET and CT scans into a single procedure called a PET-CT scan, which provides both anatomical and functional information about the cancer.^[21]

For certain patients, doctors may also order a magnetic resonance imaging (MRI) scan of the brain. This test checks whether lung cancer has spread to the brain, which is important for treatment planning even though brain metastases would change the diagnosis from stage III to stage IV.^[11]

Obtaining Tissue Samples

While imaging tests can show suspicious masses, the only way to definitively diagnose lung cancer is by examining actual cancer cells under a microscope. This requires obtaining a tissue sample through a procedure called a biopsy. Several different methods can be used to collect tissue from a suspected lung tumor.

A bronchoscopy is one common approach. During this procedure, a doctor inserts a thin, flexible tube with a camera on the end through your mouth or nose and down into your airways. This allows them to view the inside of your lungs and collect small tissue samples from suspicious areas. Bronchoscopy is particularly useful when tumors are located in the central airways.^[16]

For tumors located in the outer parts of the lungs, doctors may use a needle biopsy guided by CT imaging. In this procedure, a radiologist inserts a thin needle through your chest wall and into the tumor to extract tissue samples. The CT scan helps guide the needle to the exact location of the tumor.

In some cases, a more invasive surgical procedure may be necessary to obtain adequate tissue samples. Video-assisted thoracic surgery (VATS) involves making small incisions in the chest and inserting a camera and surgical instruments to examine the lungs and collect tissue. Mediastinoscopy is another surgical approach where a surgeon makes a small incision at the base of the neck to access and biopsy lymph nodes in the space between the lungs, called the mediastinum.^[16]

Once tissue samples are obtained, pathologists examine them under a microscope to confirm whether cancer is present and identify the specific type of NSCLC. The three main types are adenocarcinoma (which usually forms in the outer portions of the lungs), squamous cell carcinoma (which typically starts in the central airways), and large cell carcinoma (which can develop anywhere in the lungs).^[16]

Determining Cancer Stage

After confirming that you have NSCLC, doctors must determine the stage of your cancer. Stage III is defined by specific characteristics related to tumor size, lymph node involvement, and whether the cancer has spread to distant sites.

Doctors use the TNM staging system to classify NSCLC. The T refers to the size and extent of the primary tumor, N indicates whether cancer has spread to nearby lymph nodes, and M shows whether the disease has metastasized to distant organs. All stage III cancers are classified as M0, meaning there is no distant metastasis, but they vary in their T and N values.^[6]

Stage III NSCLC is divided into three substages: 3A, 3B, and 3C. Each substage represents increasingly extensive disease within the chest. Stage 3A typically involves smaller tumors with spread to lymph nodes on the same side of the chest as the primary tumor. Stage 3B includes larger tumors or cancer that has spread to lymph nodes on the opposite side of the chest, in the neck, or above the collarbone. Stage 3C represents the most advanced stage III disease, with extensive tumor growth and widespread lymph node involvement within the chest.^[1]^[2]

The imaging tests and biopsies described above work together to provide all the information needed for accurate staging. The CT scan shows tumor size and location, the PET scan identifies active cancer in lymph nodes, and tissue samples from lymph node biopsies confirm whether cancer cells are actually present in those nodes.

Additional Diagnostic Tests

Beyond standard imaging and biopsies, doctors may order additional tests to evaluate your overall health and how well your lungs are functioning. These tests help determine whether you are healthy enough to undergo certain treatments.

Pulmonary function tests measure how well your lungs work by assessing how much air you can inhale and exhale and how efficiently your lungs transfer oxygen to your blood. These tests are especially important if surgery is being considered, because removing part or all of a lung requires that your remaining lung tissue can adequately support your breathing.^[16]

Blood tests are also routine parts of the diagnostic workup. While no blood test can diagnose lung cancer by itself, blood work provides information about your overall health, kidney function, liver function, and blood cell counts. These factors influence which treatments you can safely receive.

Diagnostics for Clinical Trial Qualification

If you are considering enrolling in a clinical trial for stage III NSCLC, you will likely need to undergo additional specialized testing beyond the standard diagnostic procedures. Clinical trials have specific eligibility criteria, and certain tests are required to determine whether you qualify for participation.

Molecular and Genetic Testing

One of the most important categories of tests for clinical trial qualification involves analyzing your tumor tissue at the molecular level. These tests look for specific genetic mutations or biomarkers that might make your cancer respond to targeted therapies being studied in trials.

Epidermal growth factor receptor (EGFR) testing checks whether your tumor has mutations in the EGFR gene. EGFR is a protein on the surface of cells that helps them grow and divide. When mutations occur in this gene, cancer cells can grow and divide more rapidly. If your tumor has an EGFR mutation, you may be eligible for clinical trials testing drugs that specifically target this abnormality.^[8]

Similarly, testing for ALK (anaplastic lymphoma kinase) gene rearrangements can open doors to clinical trials of ALK inhibitors. Other molecular markers that may be tested include ROS1 rearrangements, BRAF mutations, and MET alterations. Each of these represents a potential target for specialized treatments being evaluated in research studies.^[8]

Another important biomarker is PD-L1 (programmed death-ligand 1), a protein that can be found on the surface of some cancer cells. Testing for PD-L1 expression helps predict whether your cancer might respond to immunotherapy drugs that help your immune system recognize and attack cancer cells. Many clinical trials for stage III NSCLC involving immunotherapy require PD-L1 testing as part of their eligibility criteria.^[13]

These molecular tests are typically performed on the same tissue samples obtained during your initial biopsy. However, if the original biopsy did not yield enough tissue for comprehensive molecular testing, you may need to undergo an additional biopsy procedure to obtain more material.

Performance Status Assessment

Clinical trials have strict requirements about how well patients must be functioning before they can enroll. Doctors assess your performance status, which is a measure of how cancer is affecting your daily activities and your ability to care for yourself. Two common scales are used: the Eastern Cooperative Oncology Group (ECOG) scale and the Karnofsky Performance Status scale.

These assessments involve your doctor evaluating whether you can carry out normal activities, whether you spend significant time in bed or a chair, and whether you need help with basic self-care tasks. Most clinical trials for stage III NSCLC require that patients have good performance status, meaning they can carry out most daily activities even if they experience some symptoms.^[7]

Verification of Treatment Response

For some clinical trials, particularly those testing new treatments after standard chemotherapy and radiation, you will need imaging tests to document how your cancer responded to initial treatment. These may include repeat CT scans or PET scans performed after you complete initial chemoradiation therapy (chemotherapy combined with radiation therapy). The trial protocol may specify that your cancer must have responded to or stabilized with initial treatment before you can receive the investigational therapy being studied.^[2]^[19]

⚠️ Important

Not all patients with stage III NSCLC will be eligible for clinical trials, even if they meet basic health requirements. Trial eligibility depends on many factors including the specific substage of your cancer, previous treatments you have received, other medical conditions you may have, and whether your tumor has the molecular characteristics being studied. Your healthcare team can help you understand which trials might be options for your specific situation.

Baseline Testing for Safety Monitoring

Before enrolling in a clinical trial, you will undergo comprehensive baseline testing to establish your health status before starting the investigational treatment. This creates a reference point that allows researchers to monitor for side effects and measure changes during the study.

Baseline tests typically include detailed blood work to assess your organ function, particularly your liver, kidneys, and bone marrow. Imaging scans document the exact size and location of all tumor sites. Heart function tests such as electrocardiograms or echocardiograms may be required, especially if the investigational drug could potentially affect cardiovascular health. These baseline assessments will be repeated at regular intervals throughout the trial to track your response to treatment and detect any concerning side effects early.

Understanding the diagnostic requirements for clinical trials helps you prepare for what may be a more extensive testing process than standard care requires. However, this thorough evaluation serves important purposes: it ensures that the treatments being studied are given to patients most likely to benefit, and it provides the detailed monitoring necessary to establish whether new therapies are safe and effective.

Prognosis and Survival Rate

Prognosis

The prognosis for stage III non-small cell lung cancer depends on multiple factors that doctors consider when estimating likely outcomes. Stage III is considered locally advanced disease, positioned between earlier localized stages that may be curable with surgery alone and stage IV metastatic disease where cure is rarely possible.^[3] The specific substage—whether 3A, 3B, or 3C—significantly influences prognosis, with earlier substages generally having better outcomes than more advanced ones.

Several patient-specific factors affect prognosis beyond just the cancer stage. Your overall health and ability to perform daily activities, measured as performance status, plays a crucial role in determining which treatments you can tolerate and how well you might respond. The presence of certain molecular markers like EGFR mutations or ALK rearrangements can improve prognosis because targeted therapies are available for these tumor types. The extent of lymph node involvement within the chest and whether the tumor has grown into vital structures like major blood vessels or the heart also influence outcomes.^[13]

Treatment response is perhaps the most important prognostic factor. Patients whose tumors shrink significantly with initial chemotherapy and radiation therapy generally have better long-term outcomes than those whose cancers do not respond well. For patients with stage 3A disease who are healthy enough for surgery after chemoradiation shrinks their tumors, the prognosis may be more favorable than for those with unresectable disease.^[8]

Survival Rate

Survival rates for stage III NSCLC provide general guidance about outcomes but should be interpreted carefully because they represent averages across diverse patient populations. Patients who receive combined chemotherapy and radiation therapy have achieved approximately 27 percent three-year survival in clinical studies.^[7] This means that about one in four patients with stage III NSCLC treated with chemoradiation will survive at least three years after diagnosis.

Recent advances in treatment, particularly the addition of immunotherapy after chemoradiation for patients with unresectable stage III NSCLC, have shown promise for improving these survival statistics. However, survival rates vary considerably based on the specific substage and individual patient characteristics. Stage 3A patients who undergo successful surgery after initial treatment may have better long-term survival than those with stage 3B or 3C disease who cannot have surgery.^[13]

It is important to understand that survival statistics are based on patients diagnosed and treated in previous years, and newer treatments may improve outcomes for patients diagnosed today. Additionally, these numbers represent averages—some patients live much longer than average while others face shorter survival times. Your individual prognosis depends on your specific circumstances, which your healthcare team can discuss with you in detail.